Fortunately, the S&P 500 recovered to new all-time highs by August 2020 and is now up about 150% from its COVID lows.

In the first major deal at MIT’s ambitious overhaul of the old Volpe Center in Kendall Square, Cambridge drugmaker Biogen ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three buildings to one.

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

Biogen/Eisai’s LEQEMBI (lecanemab) Overview LEQEMBI, developed by Biogen and Eisai, is a humanized IgG1 monoclonal antibody targeting both soluble aggregated forms (protofibrils) and insoluble ...

An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...